Amy C. Peterson - 19 Jul 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
EVP, Chief Development Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Amy C. Peterson
Issuer symbol
CTMX
Transactions as of
19 Jul 2022
Net transactions value
-$10,612
Form type
4
Filing time
21 Jul 2022, 16:11:42 UTC
Previous filing
04 Feb 2022
Next filing
20 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +20,000 +40% $0.000000 70,153 19 Jul 2022 Direct F1, F2, F3
transaction CTMX Common Stock Sale $10,612 -7,463 -11% $1.42 62,690 20 Jul 2022 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
F2 Includes 40,000 restricted stock units.
F3 Reflects the adjusted total which includes the purchase of 3,732 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
F4 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.